Valvular heart disease is characterized by damage to or a defect in one of the four heart valves namely the mitral valve, aortic valve, tricuspid valve, and pulmonary valve.
This report contains market size and forecasts of Valvular Heart Disease Treatment in Global, including the following market information:
Global Valvular Heart Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Valvular Heart Disease Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Cardiac Catheterization Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Valvular Heart Disease Treatment include Abbott Laboratories, B. Braun Melsungen AG, Boston Scientific Corp., Medtronic, CryoLife Inc., Edwards Lifesciences Corporation, LivaNova PLC, Neovasc Inc. and Micro Interventional Devices, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Valvular Heart Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Valvular Heart Disease Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Valvular Heart Disease Treatment Market Segment Percentages, by Type, 2021 (%)
- Cardiac Catheterization
- Electrocardiogram (ECG)
- Chest X-Ray
- Stress Test
- Others
Global Valvular Heart Disease Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Valvular Heart Disease Treatment Market Segment Percentages, by Application, 2021 (%)
- Hospital & Clinics
- Ambulatory Surgical Centers
- Research Institutes
Global Valvular Heart Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Valvular Heart Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Valvular Heart Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Valvular Heart Disease Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Abbott Laboratories
- B. Braun Melsungen AG
- Boston Scientific Corp.
- Medtronic
- CryoLife Inc.
- Edwards Lifesciences Corporation
- LivaNova PLC
- Neovasc Inc.
- Micro Interventional Devices
- Symetis SA
- Jenavalve Technology
- TTK Healthcare Limited
- Colibri Heart Valve
- Lepu Medical Technology Co.
- Braile Biom?dica
